Oglemilast is primarily used in the treatment of inflammatory diseases, particularly those affecting the respiratory system. It functions as a phosphodiesterase-4 (PDE-4) inhibitor, which helps reduce inflammation by increasing levels of cyclic AMP in cells. This mechanism makes it effective in managing conditions like chronic obstructive pulmonary disease (COPD) and asthma. By controlling inflammation, it helps improve lung function and reduces the frequency of exacerbations in patients. Additionally, its anti-inflammatory properties are being explored for potential use in other inflammatory disorders, such as rheumatoid arthritis and psoriasis. Oglemilast offers a targeted approach to managing chronic inflammatory conditions, improving patient quality of life.